Long-term Microphysiological Sample Imaging for Evaluation of Polypharmacy in Liver

DeLIVERY develops a microphysiological system to personalize healthcare by investigating drug interactions in elderly patients, aiming to improve treatment outcomes and quality of life.

Subsidie
€ 3.547.046
2022

Projectdetails

Introduction

DeLIVERY aims to build a radically new technology for personalized health care, which provides, for the first time, the possibility to investigate polypharmacy on individual patients.

Background

Polypharmacy is the effect that the many combinations and permutations of drug mixtures, which are typically prescribed to the chronically sick or the elderly population (e.g., painkillers, beta blockers, blood thinners, anti-depressants, and statins), have on the human body.

Polypharmacy is becoming a major issue in the ageing population, as well over 10% of hospital admissions for people over 60 years of age are due to currently unknown interactions of the multiple drugs being prescribed by the specialized physicians and general practitioners routinely visited by the elderly.

Current Challenges

Currently, no single platform exists that can be utilized in a highly parallelized fashion to monitor such effects at the cellular and tissue level.

DeLIVERY's Solution

DeLIVERY will provide an integrated microphysiological system (MPS) culture and microscopic imaging platform specifically for the purpose of maintaining, treating, and long-term imaging of patient-specific cells within their microenvironment.

This MPS platform will allow physicians, biomedical scientists, and researchers to determine the individual response of human tissue biopsies to a combination of multiple drugs.

Impact on Healthcare

DeLIVERY will enable individualized treatment options, providing essential tools towards a better quality of life for older people by allowing improved personalized healthcare.

Novel medicines with the potential to reverse the effects of ageing and non-alcoholic fatty liver disease (NAFLD) will be tested within typical polypharmacy contexts to determine possible interactions, and the DeLIVERY MPS system will be the purpose-built platform to provide this service.

Future Directions

Such a system also requires a paradigm shift in microscopy - away from the single, bulky instrument providing one imaging modality towards compact and modular, yet still high-end, devices.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 3.547.046
Totale projectbegroting€ 3.547.046

Tijdlijn

Startdatum1-5-2022
Einddatum30-4-2026
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • UNIVERSITAET BIELEFELDpenvoerder
  • UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET
  • VRIJE UNIVERSITEIT BRUSSEL
  • EVANGELISCHES KLINIKUM BETHEL GGMBH
  • EXCELITAS PCO GMBH
  • CHERRY BIOTECH
  • THE HENRYK NIEWODNICZANSKI INSTITUTE OF NUCLEAR PHYSICS, POLISH ACADEMY OF SCIENCES

Land(en)

GermanyNorwayBelgiumFrancePoland

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Personalised Adaptive Medicine

The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.

€ 1.726.876
EIC Pathfinder

Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes

This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.

€ 3.885.462
EIC Pathfinder

On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs

Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.

€ 2.606.250
EIC Pathfinder

Insight into Drug Distribution and Local Concentration using Multispectral Imaging of Fluorescent Drugs in Inflammatory Bowel Diseases

msGUIDE aims to enhance IBD treatment through a novel imaging technology that quantifies drug distribution and targets specific cells for personalized medicine and real-time monitoring.

€ 4.027.964

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

Servicable Digital Biomaker Platform

MS Sherpa voert een haalbaarheidsstudie uit naar een digitaal biomarkerplatform om de effectiviteit van medicijnen in de dagelijkse praktijk te verbeteren en onnodig medicijngebruik te verminderen.

€ 20.000
ERC Starting...

Lifetime Metabolomics for Paediatric Liver Cancer Detection and Therapy Assessment Using Organ-on-Chip Platforms

LIFETIME aims to develop a scalable platform for lifetime metabolomics to enhance early diagnosis and treatment of hepatoblastoma through advanced profiling and tracking of metabolic changes.

€ 2.499.318
EIC Transition

IDEFIX Multiorgan toxicity and efficacy test platform

Cherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions.

€ 2.496.073
ERC Consolid...

Drug DELIvery to the brain via CHOroid Plexus targeting

This project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders.

€ 1.999.756
EIC Accelerator

Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development

Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.

€ 2.499.831